When to optimise therapy
- To understand the underlying pathophysiology that leads to hyperglycaemia in type 2 diabetes mellitus (T2DM)
- To discuss the concept of clinical inertia
- To apply the guidelines from theory into practice
- To understand the considerations for developing individualised care
- To discuss case studies
Understanding GLP-1 Receptor Agonists:
- To understand the incretin effect
- To understand the effects of Glucagon-like Peptide-1 (GLP-1) in humans
- To understand the effects of GLP-1 receptor agonists in type 2 diabetes
- To explore ways to ensure timely initiation of GLP-1 receptor agonists
Choosing a GLP-1 Receptor Agonist Therapy
- To understand how the physiological benefits of native GLP-1 have been translated into the therapeutic class of GLP-1 RAs
- To explore the impact of cardiovascular data on evolving guidance
- To explore differences between the GLP-1 Receptor Agonists with a human GLP-1 backbone
- To use case studies to illustrate key points
- To examine existing guidelines and their application to practice
Practicalities of starting a GLP-1 RA therapy
- To understand how a thorough assessment of the patient’s baseline parameters can support implementation of GLP-1 RA therapy
- To develop an awareness of the various GLP-1 RA devices and methods of administration
- To understand the process involved in the initiation of GLP-1 RA therapy, including special considerations
- To determine necessary factors for ongoing management
